Early B-Cell Return in Patients with Autoimmune Disease Treated with Rituximab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0813; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "14 had received concomitant cyclophosphamide for induction. Conclusion Early B-cell reconstitution occurs in a small but clinically meaningful subset of patients receiving rituximab maintenance therapy, with significant variability across autoimmune disease subtypes. Early B-cell return observed at 4-months highlights the potential inadequacy of standard fixed-interval dosing and supports the role of peripheral B-cell monitoring to guide personalized rituximab re-dosing strategies."
Clinical • ANCA Vasculitis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • Vasculitis
|
|
Ashima Chadha; John L. Niles; Sydney Aaron; James L. Chung; Karen A. Laliberte; Orhan Efe; Harish Shanthanu Seethapathy; Ayman Al Jurdi
|